Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993786 | 0.82 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30015279 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL279594 | 0.79 | MMP12 (1.00) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL29452973 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL302933 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL861110 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL707058 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8184077 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL277585 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4137452 | 0.79 | MMP12 (0.65) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112918-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4108659-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022081912-A2 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3464272-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-10858359-B2 | Heterocyclic ring derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20190127378-A1 | NOVEL HETEROCYCLIC RING DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| WO-2017211303-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017199265-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2017-11-23 | — | — | WO | disclosed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858359-B2 | Heterocyclic ring derivatives useful as SHP2 inhibitors | PTPRJ, PTPN22, PTPRCAP | MMP12 2080/4885PARP1 4690/4885ALDH1A1 3089/4885 |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | MMP12 258/4885PARP1 1113/4885ALDH1A1 2579/4885 |
| US-20190127378-A1 | NOVEL HETEROCYCLIC RING DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN22, PTPN1, PTPRJ | MMP12 2594/4885PARP1 4789/4885ALDH1A1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.